Related Experiment Video
Updated: May 30, 2025
05:10
Drug Repurposing Hypothesis Generation Using the "RE:fine Drugs" System
Published on: December 11, 2016
9.4K
From Vision to Reality: The EU's Pharmaceutical Reforms and the Path to Improved Access
Caitlin Main1, Cathrin Schäfer2, Panos Kanavos3
1Department of Health Policy and Medical Technology Research Group, LSE Health, London School of Economics and Political Science, London, UK. c.a.main@lse.ac.uk.
Pharmacoeconomics - Open
|January 25, 2025
Summary
New European regulations for health technology assessment and pharmaceutical legislation may improve oncology medicine access but risk unintended consequences. Policy adaptation and collaboration are crucial for equitable and timely patient treatment across the European Union.
Area of Science:
- Health Policy and Economics
- Oncology Drug Access
- European Union Healthcare Regulation
Background:
- Significant disparities exist in European Union (EU) member states regarding access to oncology medicines, impacting patient outcomes.
- Availability and timely access to cancer treatments vary considerably across and within EU countries.
Purpose of the Study:
- To analyze the potential impacts of the new European Health Technology Assessment Regulation (HTAR) on oncology medicine access.
- To examine the implications of proposed pharmaceutical legislation reforms on EU-wide medicine launches and national systems.
- To identify potential unintended consequences and propose policy adaptations for equitable access to cancer treatments.
Main Methods:
- Discussion and analysis of the intersection between the European Health Technology Assessment Regulation (HTAR) and proposed pharmaceutical legislation.
- Evaluation of the potential effects of these regulatory changes on the standardization of clinical evaluations and national healthcare needs.
- Assessment of the feasibility challenges for manufacturers concerning EU-wide medicine launches within diverse national pricing and reimbursement landscapes.
Main Results:
- The HTAR may streamline evaluations but risks oversimplifying national healthcare needs, potentially conflicting with advanced assessment systems.
- Pharmaceutical legislation reforms aiming for EU-wide launches may challenge manufacturers due to complex national pricing and reimbursement systems.
- Both initiatives could lead to increased administrative burdens, delays in access, and potential deterrents to innovation in Europe.
Conclusions:
- The new European regulations represent a shift towards collaborative healthcare policy but require careful adaptation to avoid negative consequences.
- Ensuring equitable and timely access to oncology treatments necessitates addressing potential conflicts between standardized evaluations and diverse national needs.
- Multi-stakeholder collaboration is essential to mitigate risks and achieve the intended goals of improved access to cancer medicines across the EU.
More Related Videos
Related Concept Videos
01:03Drug Control Governance: Regulatory Bodies and Their Impact
138
Drug control governance involves the oversight and regulation of pharmaceuticals to ensure their safety and efficacy while preventing illegal drug use and trafficking. Regulatory bodies, including the US Food and Drug Administration (FDA) and the European Union's European Medicines Agency (EMA), play a central role in this process. These agencies evaluate the safety and efficacy of drugs before they can be marketed. They fund clinical trials and assess the benefits and risks associated with...
138
01:25Drug Regulation
1.3K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.3K
01:26Methods Of Healthcare Delivery System
3.1K
At the different levels of the healthcare system, we see varying methods of healthcare used. These methods include managed care systems, case management, and primary healthcare.
Managed Care System:
The managed care system is designed to control the cost while maintaining the quality of care. The patient's care from admission to discharge is planned by the primary care provider or the case manager, also known as the gatekeeper. In a managed care system, the number of care providers is...
Managed Care System:
The managed care system is designed to control the cost while maintaining the quality of care. The patient's care from admission to discharge is planned by the primary care provider or the case manager, also known as the gatekeeper. In a managed care system, the number of care providers is...
3.1K
01:29Issues And Trends In Healthcare Delivery System
5.6K
The issues and trends in healthcare delivery are constantly changing. The COVID-19 pandemic is one recent issue that wreaked havoc on healthcare systems, causing a shortage of healthcare workers, high demand for medicines and supplies, and increased medical expenditure due to a lack of insurance. Other issues include rising healthcare costs and care fragmentation.
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
Cost Containment
Payment for healthcare services has historically promoted adoption of costly and often unnecessary or inefficient...
5.6K
01:18Introduction To Health Care Delivery System
2.6K
The healthcare system is constantly changing and complex. Various services are available from different healthcare providers, but gaining access to these services has become challenging for people with limited healthcare insurance. Uninsured people present a challenge to healthcare because they frequently postpone or forego treatment.
The Institute of Medicine (IOM) advocates for a patient-centered, effective, safe, timely, equitable, and effective healthcare system. The National Priorities...
The Institute of Medicine (IOM) advocates for a patient-centered, effective, safe, timely, equitable, and effective healthcare system. The National Priorities...
2.6K
01:02Prescription, Nonprescription and Orphan Drugs
683
Prescription drugs require a prescription from a medical practitioner and can only be obtained from a pharmacy. They have many applications, including treating pain, anxiety, and hypertension.
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
The misuse and addiction to prescription drugs is a growing problem that can affect people of all age groups, specifically teenagers. This can happen when prescription medications are used in ways not intended by the prescriber, such as taking someone else's prescription or using medication for...
683